Mastodon

Suprax® (Tablets, Capsules, Granules) Instructions for Use

ATC Code

J01DD08 (Cefixime)

Active Substance

Cefixime (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Third generation cephalosporin

Pharmacotherapeutic Group

Antibiotic-cephalosporin

Pharmacological Action

A broad-spectrum semi-synthetic third-generation cephalosporin antibiotic for oral administration. It acts bactericidally. The mechanism of action is due to the inhibition of the synthesis of the pathogen’s cell membrane. Cefixime is resistant to the action of β-lactamases produced by most gram-positive and gram-negative bacteria.

In vitro, Cefixime is active against gram-positive bacteria Streptococcus agalactiae; gram-negative bacteria Haemophilus parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Providencia spp., Salmonella spp., Shigella spp., Citrobacter amalonaticus, Citrobacter diversus, Serratia marcescens.

In vitro and in clinical practice, Cefixime is active against gram-positive bacteria Streptococcus pneumoniae, Streptococcus pyogenes; gram-negative bacteria Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Escherichia coli, Proteus mirabilis, Neisseria gonorrhoeae.

The following are resistant to cefixime: Pseudomonas spp., Enterococcus (Streptococcus) serogroup D, Listeria monocytogenes, most Staphylococcus spp. (including methicillin-resistant strains), Enterobacter spp., Bacteroides fragilis, Clostridium spp.

Pharmacokinetics

When taken orally, the bioavailability of cefixime is 40-50% regardless of food intake; however, the Cmax of cefixime in serum is reached 0.8 hours faster when the drug is taken with food. Plasma protein binding, mainly with albumin, is 65%. About 50% of the dose is excreted in the urine unchanged within 24 hours, about 10% of the dose is excreted in the bile.

The T1/2 is dose-dependent and is 3-4 hours. In patients with impaired renal function with a CC of 20 to 40 ml/min, T1/2 increases to 6.4 hours; with a CC of 5-10 ml/min, it increases to 11.5 hours.

Indications

Infectious and inflammatory diseases caused by susceptible microorganisms: pharyngitis, tonsillitis, sinusitis, acute and chronic bronchitis, otitis media, uncomplicated urinary tract infections, uncomplicated gonorrhea.

ICD codes

ICD-10 code Indication
A54 Gonococcal infection
H66 Suppurative and unspecified otitis media
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N37.0 Urethritis in diseases classified elsewhere
N41 Inflammatory diseases of prostate
N77.1 Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
ICD-11 code Indication
1A7Z Gonococcal infection, unspecified
1F23.10 Candidiasis of vulva and vagina
1F65 Enterobiasis
1H0Z Unspecified infection
AA9Z Unspecified suppurative otitis media
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
GA91.Z Inflammatory and other diseases of prostate, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.1 Nonspecific urethritis
GC02.Z Urethritis and urethral syndrome, unspecified
1A94.0 Genital or urogenital tract infection caused by Herpes simplex virus
GA41 Ulcerative or erosive diseases of vulva

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets, Capsules, Granules

For adults and children over 12 years of age weighing more than 50 kg, the daily dose is 400 mg (once a day or 200 mg twice a day). The duration of the course of treatment is 7-10 days. For uncomplicated gonorrhea – 400 mg as a single dose.

For children under 12 years of age – 8 mg/kg of body weight once a day or 4 mg/kg every 12 hours.

For infections caused by Streptococcus pyogenes, the course of treatment should be at least 10 days.

In case of impaired renal function (with CC from 21 to 60 ml/min) or in patients on hemodialysis, the daily dose should be reduced by 25%.

With CC≤20 ml/min or in patients on peritoneal dialysis, the daily dose should be halved.

Adverse Reactions

From the digestive system: dry mouth, anorexia, diarrhea, nausea, vomiting, abdominal pain, flatulence, transient increase in the activity of hepatic transaminases and alkaline phosphatase, hyperbilirubinemia, jaundice, gastrointestinal candidiasis, dysbacteriosis; rarely – stomatitis, glossitis, pseudomembranous enterocolitis.

From the hematopoietic system: leukopenia, thrombocytopenia, neutropenia, hemolytic anemia.

From the central nervous system: dizziness, headache.

From the urinary system: interstitial nephritis.

Allergic reactions: skin itching, urticaria, skin hyperemia, eosinophilia, fever.

Contraindications

Hypersensitivity to cephalosporins and penicillins.

Use in Pregnancy and Lactation

Use during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.

If it is necessary to use during lactation, breastfeeding should be discontinued.

Use in Renal Impairment

In case of impaired renal function (with CC from 21 to 60 ml/min) or in patients on hemodialysis, the daily dose should be reduced by 25%. With CC≤20 ml/min, the daily dose should be halved.

Pediatric Use

Should be used with caution in children under 6 months of age.

Geriatric Use

Should be used with caution in elderly patients.

Special Precautions

Should be used with caution in elderly patients, patients with chronic renal failure or a history of pseudomembranous colitis, and in children under 6 months of age.

With prolonged use, disruption of the normal intestinal microflora is possible, which can lead to the growth of Clostridium difficile and cause the development of severe diarrhea and pseudomembranous colitis.

In patients with a history of allergic reactions to penicillins, manifestations of hypersensitivity to cephalosporin antibiotics are possible.

During treatment, a positive direct Coombs test and a false-positive urine glucose reaction are possible.

Storage Conditions

Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Astellas Pharma Europe B.V. (Netherlands)

Manufactured By

Facta Farmaceutici, S.p.A. (Italy)

Or

Jazeera Pharmaceutical Industries (Saudi Arabia)

On Behalf Of

ASTELLAS PHARMA EUROPE, B.V. (Netherlands)

Packaging and Quality Control Release

HIKMA PHARMACEUTICALS (Jordan)

Or Packaging and Production Quality Control

FACTA FARMACEUTICI, S.P.A. (Italy)

Dosage Form

Bottle Rx Icon Suprax® Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe

Dosage Form, Packaging, and Composition

Granules for the preparation of an oral suspension from almost white to cream-colored, fine; after mixing, a suspension from almost white to cream-colored with a sweet strawberry aroma is formed.

1 bottle 5 ml of prepared susp.
Cefixime trihydrate (micronized) 1.402 g 100 mg
   (equivalent to 1.2 g of cefixime + 4% overfill)

Excipients: sodium benzoate – 0.03 g, sucrose – 30.225 g, xanthan gum – 0.155 g, strawberry flavor – 0.048 g.

30.3-35.0 g – dark glass bottles (1) complete with a 5 ml dosing syringe – cardboard packs.

Marketing Authorization Holder

Cheplapharm Arzneimittel, GmbH (Germany)

Manufactured By

ACS Dobfar, S.p.A. (Italy)

Dosage Form

Bottle Rx Icon Suprax® Capsules 400 mg: 6 pcs.

Dosage Form, Packaging, and Composition

Capsules hard, size “0”, with a purple cap and a white body; with the code “H808” printed with food ink; capsule contents – a yellowish-white mixture of powder and granules.

1 caps.
Cefixime trihydrate 466 mg,
   Equivalent to cefixime content 400 mg

Excipients: colloidal silicon dioxide, magnesium stearate, macrogol glyceryl hydroxystearate (polyoxyl 40 stearate), calcium carmellose (calcium carboxymethylcellulose).

Composition of gelatin capsules: titanium dioxide, dye azorubine (E122), indigo carmine (E132), gelatin.
Composition of food ink: shellac, ethanol, isopropanol, butanol, propylene glycol, sodium hydroxide, povidone, titanium dioxide.

6 pcs. – blisters (1) – cardboard packs.

Marketing Authorization Holder

Cheplapharm Arzneimittel, GmbH (Germany)

Manufactured By

ACS Dobfar, S.p.A. (Italy)

Dosage Form

Bottle Rx Icon Suprax® Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe

Dosage Form, Packaging, and Composition

Granules for the preparation of an oral suspension from almost white to cream-colored, fine; after mixing, a suspension from almost white to cream-colored with a sweet strawberry aroma is formed.

1 bottle 5 ml of prepared susp.
Cefixime trihydrate (micronized) 1.402 g 100 mg
   (equivalent to 1.2 g of cefixime + 4% overfill)

Excipients: sodium benzoate – 0.03 g, sucrose – 30.225 g, xanthan gum – 0.155 g, strawberry flavor – 0.048 g.

30.3-35.0 g – dark glass bottles (1) complete with a 5 ml dosing syringe – cardboard packs.

Marketing Authorization Holder

Cheplapharm Arzneimittel, GmbH (Germany)

Manufactured By

A.Menarini Manufacturing Logistics and Services, S.r.l. (Italy)

Packaging and Quality Control Release

A.Menarini Manufacturing Logistics and Services, S.r.L. (Italy)

Or

ORTAT, JSC (Russia)

Dosage Form

Bottle Rx Icon Suprax® Solutab® Dispersible tablets 400 mg: 1, 5, 7 or 10 pcs.

Dosage Form, Packaging, and Composition

Dispersible tablets light orange in color, oblong, with a score line on both sides, with a strawberry odor.

1 tab.
Cefixime trihydrate 447.7 mg,
   Equivalent to cefixime content 400 mg

Excipients: microcrystalline cellulose – 44.5 mg, low-substituted hypromellose – 40 mg, colloidal silicon dioxide – 5 mg, povidone – 5 mg, magnesium stearate – 10 mg, calcium saccharin tris sesquihydrate – 20 mg, strawberry flavor FA15757 – 5 mg, strawberry flavor PV4284 – 2.5 mg, dye “sunset yellow” (E110) – 0.3 mg.

1 pc. – blisters (1) – cardboard packs.
5 pcs. – blisters (1) – cardboard packs.
5 pcs. – blisters (2) – cardboard packs.
7 pcs. – blisters (1) – cardboard packs.

TABLE OF CONTENTS